Dr. David Samadi Says Surgery Is Better Than Radiation

There’s a probability that Mitt Romney might be running for a seat in the senate again in the next elections. Orrin Hatch will vacate his Utah senate seat sometime soon and Romney might be waiting on the line to replace him. Romney’s recent announcement that he has successfully undergone prostrate surgery might have fanned this speculation. He was diagnosed to have a tumor and disclosing his health condition to the electorate is a strong indication of his intention to run again.

The announcement indicated that Dr. Thomas Ahlering performed the successful operation on Romney at UC Irvine Hospital in California. The former senator and presidential candidate is not the first US politician to successfully undergo prostate cancer operation. Colin Powell, former State Secretary had his in 2003 where his prostate gland was removed. The most recent one is John Kerry, another US politician who ran for US President and has also undergone a successful prostate surgery. Reports say that he has not suffered any recurrence after the operation.

Read: Dr. David Samadi: Mitt Romney’s prostate cancer prognosis good after successfully treated with surgery 

All these men were diagnosed with prostate cancer in their advanced years. It goes to say that this malady usually develops in older men. The stats seem to prove this fact because in 10 cases of prostate cancer, 6 are from men 65 years old and older. Prostate cancer, as the stats reveal, rarely develops in men under 40 years of age. On the average, the disease hits men that are 66 years old.

If a man of this age is diagnosed with the disease, he has two options: surgery or radiation. The experiences of Romney, Powell and Kerry seem to point out that surgery is the better option. Dr. David Samadi is of the same opinion. He believes that patients with the disease are better off undergoing surgery than radiation treatment. He cites several studies to prove his point. Dr. Samadi added that patients who undergo radiation are twice at risk of dying from the disease and that they could die sooner by one-and-a-half times than those who undergo surgery.

Dr. Samadi knows what he is saying because he has studied the disease so well and is also well-experienced in the area of treating prostate cancer, he being a board-certified urologist. He is the Chairman of Urology at Lenox Hill Hospital and its Chief of Robotic Surgery. Dr. Samadi is a native of Iran of Jewish descent but migrated to the United States during the Iranian Revolution. He earned his degree in medicine in 1994 from S.U.N.Y.

For More info: www.linkedin.com/in/davidsamadi

Clay Siegall Shares More Assurance In Delivering Support To Cancer Research


Research projects aimed at eliminating cancer have helped to offer different types of solutions Many companies have been pursuing this field with the hope of getting a technology that can make it easier to treat cancer even in extreme levels. This growth in the interest to find a solution has seen more companies join the field and among those that have recorded success is Seattle Genetics, a leading biotechnology company that has concentrated for many years on finding the best ways of treating cancer. Clay Siegall founded the company with the focus on research and exploring different technologies to improve the way people receive treatment.

Since its first day, Seattle Genetics has been working with experts from various industries, who have offered support to make the research programs possible. One of the most recent achievements Seattle Genetics has been celebrating is the successful development of the ADC Technology. Through the technology, cancer cells are targeted while ignoring other cells during treatment. The technology ensures there is no damage to healthy cells while treating cancer. Its success has seen several biotechnology companies sign partnerships to support the development of the technology. Clay Siegall also supported the development of ADCETRIS, which is a unique drug pipeline that supports cancer treatment.

About Clay Siegall

As an expert who has worked in the clinical science industry for over three decades, Clay Siegall has gained a lot of skills and experience that saw him launch and effectively manage Seattle Genetics, a leading company in the biotechnology field that has successfully been supporting cancer research. Clay is a clinical scientist and this explains why he launched the company on the idea of research and the development of new and better cancer treatment options.

He first pursued Zoology at the Maryland University before he moved to the University of Washington to pursue his PhD in Genetics. He worked with several companies before launching Seattle Genetics. He also worked at the National Institute of Health Sciences, thereby gaining useful skills and experience that allowed him to launch and run Seattle Genetics seamlessly to become a renowned biotechnology company.